<DOC>
	<DOCNO>NCT01734824</DOCNO>
	<brief_summary>The etiology bone marrow edema ( BME ) still uncertain . Several study report therapeutic success antiresorptive drug . This study investigate antiresorptive osteoanabolic drug versus placebo BME</brief_summary>
	<brief_title>Treatment Atraumatic Bone Marrow Edema With Denosumab Teriparatide v Placebo</brief_title>
	<detailed_description>Patients assign receive either denosumab 60mg sc ( ) placebo daily teriparatide sc three month placebo . MRI examination baseline three month perform . Serum bone turnover marker evaluate well QoL questionnaire .</detailed_description>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>MRI diagnose bone marrow edema prior antiresorptive osteoanabolic treatment prior therapy strontium ranelate Hyper/hypocalcemia malignancy pregnancy contraindication denosumab teriparatide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>bone marrow edema , denosumab , PTH 1-84</keyword>
</DOC>